Altris AI, an advanced artificial intelligence (AI) platform for OCT analysis, is trusted by over 500 eye care businesses worldwide. Unlike other solutions that rely on pre-existing assumptions about specific biomarkers or pathologies, Altris AI detects over 70 retinal conditions on OCT scans without requiring targeted searches.
The platform is FDA-cleared, CE-certified, GDPR-compliant, and available to all eye care specialists with a free trial option.

In January 2025, Altris AI will launch an AI-powered glaucoma optic disc (OD) analysis module. This new functionality builds upon the existing ganglion cell complex (GCC) asymmetry analysis module, which is used for early glaucoma risk assessment. Together, these two modules enhance the early diagnosis, monitoring, and management of glaucoma, bringing a new level of precision to eye care.

OCT provides high-resolution imaging of retinal structures, allowing for precise measurements of the optic disc and macula ganglion cell complex integrity. Altris AI’s optic disc analysis takes this further by offering a comprehensive view of structural damage, enabling detailed glaucoma assessments that support more effective treatment decisions. This marks a transformative shift in glaucoma detection and management.

Using advanced machine learning algorithms, Altris AI detects early glaucomatous changes with exceptional sensitivity and specificity. It highlights subtle structural abnormalities, flags areas of concern, and identifies early disease stages while enabling long-term monitoring of disease progression.

By integrating OCT imaging with Altris AI, optometrists can improve diagnostic accuracy, enable earlier intervention, and optimize long-term visual outcomes for their patients.
Dr. Maria Znamenska, MD, PhD in Ophthalmology and Chief Medical Officer at Altris AI, shared her thoughts:

“The launch of our Advanced Optic Disc Analysis module represents a significant milestone in glaucoma care. By combining the gold standard of optic disc evaluation with AI-powered precision, we’re equipping eye care professionals with the tools needed for more accurate and timely diagnoses of this vision-threatening condition. This innovation reduces false positive referrals, enhances early detection, and improves treatment planning—ultimately leading to better outcomes for patients and more efficient use of healthcare resources. With the AI-powered OD analysis, our platform empowers clinicians to elevate the standard of glaucoma care, offering hope to millions at risk of vision loss.”

About Altris AI:
Altris AI is an artificial intelligence platform for OCT analysis that detects the widest range of retinal pathologies and biomarkers on the market—more than 70. Leading the way in AI innovation, Altris AI provides transformative solutions that enhance the diagnosis, treatment, and monitoring of retinal diseases, enabling eye care professionals to deliver exceptional patient care.